The Bagsvaerd, Denmark-based company said it had net income of 91 cents per share. The results exceeded Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...

Ozempic, or semaglutide, can now be used to reduce the risk of worsening kidney disease or kidney failure in adults with type ...

Bagsværd, Denmark, 13 January 2025 – On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament ...

Novo Nordisk has started building its first brand-new manufacturing facility in Denmark since the millennium, saying it plans to spend around DKK 8.5 billion ($1.2 billion) on the plant.

But Novo Nordisk's semaglutide drugs have stronger brand recognition in the market because both drugs (Ozempic for diabetes, and Wegovy for obesity) entered earlier and have better well-known.

Bagsværd, Denmark, 17 January 2025 – Novo Nordisk today announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is a 72-week efficacy and safety trial ...